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SUMMARY: Molecular imaging is aimed at the noninvasive visualization of the expression and function
of bioactive molecules that often represent specific molecular signatures in disease processes. Any
molecular imaging procedure requires an imaging probe that is specific to a given molecular event,
which puts an important emphasis on chemistry development. In MR imaging, the past years have
witnessed significant advances in the design of molecular agents, though most of these efforts have
not yet progressed to in vivo studies. In this review, we present some examples relevant to potential
neurobiologic applications. Our aim was to show what chemistry can bring to the area of molecular MR
imaging with a focus on the 2 main classes of imaging probes: Gd3-based and PARACEST agents.
We will discuss responsive probes for the detection of metal ions such as Ca, Zn, Fe, and Cu, pH,
enzymatic activity, and oxygenation state.
ABBREVIATIONS: BBB  blood-brain barrier; BOLD  blood oxygen leveldependent; bpy 
bipyridine; C, carbon; Ca  calcium; CEST  chemical exchange saturation transfer; CO3 
carbonate; Cu  copper; DTPA  diethylene-triamine pentaacetic acid; DOTA  1,4,7,10-tetraaza-
1,4,7,10-tetrakis(carboxymethyl)cyclododecane; Eu  europium; Fe  iron; Gd  gadolinium; H 
hydrogen; HSA  human serum albumin; kex  exchange rate; M  metal ion; Mn  manganese;
N  nitrogen; O  oxygen; OH  hydroxide; PARACEST  paramagnetic CEST; PO4  phosphate;
T1,2e  electron spin relaxation times; q  number of water molecules coordinated to Gd
3;
TPENN,N,N,N-tetrakis(2-pyridylmethyl)ethylene-diamine; tpps 5,10,15,20-tetrakis-(p-sulfona-
tophenyl porphinate; tpy  terpyridine; Zn  zinc; tauR  reorientational correlation time of the
molecule; Yb  ytterbium
Molecular imaging is an emerging science area aimed atnoninvasive visualization of the expression and function
of bioactive molecules that often represent specific molecular
signatures in disease processes. It seeks the biochemical or
physiologic abnormalities underlying the disease, rather than
the structural consequences of these abnormalities. Potential
clinical applications of molecular imaging have been widely
recognized, though the limited sensitivity and specificity of
currentmolecular imaging approaches are often amajor road-
block for clinical applications. Besides clinical settings, drug
development can also largely benefit from the integration of
molecular imaging. Molecular imaging not only allows ratio-
nalization of the parameters related to disease processes but it
can also replace the common invasive research techniques
(such as histology, which requires sacrificing animals for each
time point in the experiment) by time-effective repeatable
real-time visualization of biologically relevant processes. Cur-
rently, progress in the molecular imaging area is simulta-
neously moving at 3 levels: 1) improving the imaging hard-
ware for use in preclinical and clinical settings, 2) identifying
and validating new biologically relevant imaging targets, and
3) developing innovative imaging probes. Unlike anatomic
imaging, molecular imaging always requires a molecular im-
aging probe, and this places chemistry development in a cen-
tral position.
Among all molecular imaging technologies, MR imaging is
particularly attractive. Its exceptional resolution allows ac-
quiring anatomic images in conjunction with mapping the
activity of biomarkers. Since the introduction of MR imaging
into clinical practice, contrast-enhancing agents have been
widely used to improve the relatively low sensitivity of the
technique. Conventional MR imaging contrast agents are
paramagnetic substances that enhance the water proton relax-
ation rates. Unlike optical or radiodiagnostic probes, the MR
imaging agents do not directly generate a signal intensity but
are detected via their effect on the water proton relaxation.
Given the high paramagnetism of Gd3 (it has 7 unpaired
electrons), its poly(amino carboxylate) complexes are mostly
used today in clinical practice. Gd3 complexes have a more
important effect on the longitudinal relaxation times (T1
agents) than on the transverse relaxation times (T2 agents). In
the Gd3 complexes, the poly(amino carboxylate) ligand,
such asDTPA orDOTA (Fig 1), wraps around theGd3 ion to
prevent its toxicity; however, it leaves enough room for 1water
molecule directly linked to the paramagnetic metal ion. The
exchange of this water molecule with the surrounding water is
extremely important because it will transmit the paramagnetic
effect of the Gd to the bulk water tomake themolecule detect-
able as a decreased proton relaxation time (Fig 2).
The currently used clinical agents are nonspecific. While
they help delineate the structural anatomic consequences of
diseases, they are not capable of indicating the biochemical or
physiologic abnormalities underlying them. The efficacy of
the agent to accelerate water proton relaxation, defined as re-
laxivity, has to be selectively influenced by the particular pa-
rameter/biomarker that we want to detect, to create a “smart”
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(activatable or responsive) contrast agent. The relaxation be-
havior of paramagnetic complexes and the underlying mech-
anisms have been extensively discussed elsewhere.1-3 Here we
only summarize the various modulation pathways for the re-
laxivity of Gd3-based agents. The relaxivity (paramagnetic
relaxation enhancement of water proton relaxation per milli-
molar concentration of Gd3) is inherently related to the mi-
croscopic properties of the Gd3 complex. The most impor-
tant microscopic factors are the following: 1) the number of
water molecules directly coordinated to the metal ion (hydra-
tion number), 2) the exchange rate of these water molecules
with the surrounding water, and 3) the motion dynamics of
the molecule (how fast the complex tumbles), usually charac-
terized by the reorientational correlation time of the agent (Fig
2). In principle, any of these parameters could be modulated;
however, most of the smart contrast agents function on the
basis of changes in the hydration number or in the reorienta-
tional correlation time of the molecule because they are the
easiest to predict and modulate by chemical changes. The re-
laxivity is linearly proportional to the hydration number. The
reorientational correlation time of the agent is determined by
the size and the flexibility of themolecule. Generally speaking,
slower rotation (larger size and reduced flexibility) translates
to higher relaxivity of the Gd3 complex. However, this effect
is strongly dependent on the magnetic field, and vanishes at
fields above4T.
Recently, a new class of potential paramagnetic MR imag-
ing contrast agents, based on CEST, has been explored as a
promising alternative to classic relaxivity agents.4-8 In partic-
ular, they have generated a great enthusiasm as activatable
probes. PARACEST agents are complexes of lanthanide ions
other than gadolinium, which possess paramagnetically
shifted exchangeable protons. Those protons (NH of
amides, amines, or OH of water or alcohols) are in slow
exchange with bulk water protons (Fig 3). They can be selec-
tively saturated by radio-frequency pulses applied at the ap-
Fig 1. Gd-DOTA (Dotarem; Guerbet, Aulnay-sous-Bois, France) and Gd-DTPA (Magnevist; Schering, Berlin, Germany). Two examples of clinically used Gd3 poly(amino carboxylate)
complexes. All other approved Gd3-based contrast agents are derivatives of Gd-DOTA or Gd-DTPA.
Fig 2. In Gd3-based contrast agents, the paramagnetic Gd3 ion is coordinated by an organic ligand. The water molecules directly linked to the metal exchange with bulk water, and
this exchange transmits the paramagnetic effect of Gd3 to the surrounding environment. The efficacy of the agent is mainly related to the number of water molecules bound to Gd3
(the hydration number), q (the exchange rate of the coordinated water molecule[s] with the surrounding water), kex, and the rotational correction time R.
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propriate frequency, and due to the chemical exchange be-
tween these and the water protons, their saturation will result
in a decrease of the water proton signal intensity, which be-
comes observable on an MR image. PARACEST sensors are
based on modulation of the exchange rate or the resonance
frequency of those mobile protons on the agent. The concept
of chemical exchange saturation transfer can also be applied to
nonparamagnetic endogenous molecules; however, the sig-
nals of their protons are located close to the bulk water signal
intensity, which hampers their selective saturation. PARACEST
probes are ideally suited for molecular imaging because con-
trary to Gd3-based MR imaging agents, the contrast can be
switched on and off at will by simply adjusting the pulse se-
quence parameters. Another advantage of PARACEST with
respect to relaxivity agents is the possibility of applying ratio-
metric approaches that eliminate the problem of unknown
local concentration of the agent and allow quantitative deter-
mination. Such ratiometric approaches involve the use of a
cocktail of 2 isostructural complexes: one as a reporter of a
physiologic parameter and the other as a simple concentration
marker, whereas both have an identical biodistribution.
In recent years, significant progress has been made in the
design of novel molecular MR imaging probes, though very
few of them have entered in vivo studies. With respect to neu-
roimaging, many pathologies are associated with an altered
permeability or disruption of the BBB; however, for a contrast
agent, crossing the intact BBB still remains a challenge. In this
review, we present some examples of recent development of
molecular MR imaging probes relevant to neurobiologic ap-
plications. It is not intended to be an exhaustive review but
rather an illustration of what chemistry can bring tomolecular
MR imaging. Other reviews related to molecular neuroimag-
ing, not restricted to MR imaging, have been recently pub-
lished.9-11 Here we will discuss paramagnetic lanthanide com-
plexes involving Gd3 agents and PARACEST probes and will
focus on responsive agents designed to detect metal ions, such
as Ca2, Zn2, Cu2, and Fe2/3, pH, enzymatic activity, and
oxygenation state. We have included the above metal ions be-
cause disruption of their homeostasis is associated with vari-
ous neurodegenerative diseases. Changes in the extracellular
pH and enzymatic activities can also be the signature of spe-
cific pathology processes. The in vivo noninvasive detection of
abnormalities in the concentration of these metal ions, in pH,
or in enzymatic activities might serve in the future as an im-
portant diagnostic tool of the underlying diseases. Informa-
tion on the redox status, which is an important factor govern-
ing tumor aggressiveness, can help choose the adapted tumor
treatment. We should note that many of these abnormalities
are observable in the extracellular media, which largely facili-
tates the chemical design of the imaging probes (no need for
intracellular delivery).
Imaging Probes Responsive to Metal Ions
Ca Sensing
Understanding how the brain works involves both a compre-
hension of the physiologic functioning of its individual ele-
ments (neurons and glia cells) and a description of their func-
tional architecture and the underlying networks. The activity
of networks can be studied with in vivo neuroimaging, in par-
ticular with BOLD functional MR imaging. The BOLD tech-
nique has, however, physiologic limitations linked to the vas-
cular origin of the signal intensity.12 The temporal resolution
is in the range of several seconds, and the relationship between
the BOLD signal intensity and the neural activity is still not
fully understood. One step further could be the use of bioac-
tivated contrast agents as functional markers for processes di-
rectly linked to neural signaling. For tracking the neural activ-
ity, several specific markers might be envisaged, being
responsive to the concentration of certain ions, neurotrans-
mitters, or transmembrane potentials. Very important work
in this direction has been performed during the past years by
imaging fluorescence signals reporting intracellular Ca2 fluc-
tuations.13-15 However, the intrinsic depth limitations associ-
ated with optical imaging restrict these applications to super-
ficial regions.
The extracellular concentrations ofCa2play an important
role in both physiologic and pathologic processes. Ca2 ions
are not only crucial in several steps in neuronal signaling dur-
ing normal brain activity but are also associated with a variety
of pathologies such as ischemia, hypoglycemia, and seizures.16
The involvement of Ca2 has been implicated in neurometa-
bolic disorders such as in Parkinson disease,17 Huntington
disease,18 amyotropic lateral sclerosis,19 schizophrenia,20,21
muscular dystrophy,22 etc, suggesting a broad spectral role of
Ca in neuropsychiatric disorders. While Ca2 has been an im-
portant target for MR imaging probes, so far, to our knowl-
edge, no agents responsive to neurotransmitters or transmem-
brane potentials have been reported.
Although strictly speaking, it is not a Ca2-responsive
probe,Mn2has beenwidely used to detect neural activity and
to obtain information between interconnected groups of neu-
rons in highly distributed networks.23,24 The Mn2 ion works
as a paramagnetic mimic of Ca2; therefore, it accumulates in
neurons in an activity-dependent manner. However, Mn-en-
hanced MR imaging has several drawbacks. The MR imaging
signal intensity is proportional to the Mn2 concentration in
tissue; thus, significant amounts of Mn2 are required to pro-
duce detectable contrast. Elevated Mn2 concentrations can
perturb the circuits under study and lead to toxic effects. On
the other hand, the very slow uptake of Mn2 (from hours to
days) prevents real-time Ca imaging.
Attempts toward Ca2-sensitive MR imaging probes in-
volve mainly 2 different approaches: 1) Gd-complexes with a
T1 response on interaction with Ca2 ions, and 2) a T2 agent
Fig 3. Schematic representation of a PARACEST agent with exchangeable protons on the
ligand (amine, amide, alcohol…) (gray) or on the coordinated water (white).
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based on the Ca2-related aggregation of superparamagnetic
iron nanoparticles and calmodulin.25 The main limitation of
this second approach is the relatively long time course of the
Ca-dependent aggregation (a few seconds), preventing sens-
ing of fast Ca-concentration changes.
It is much easier to achieve a fast magnetic response by
intramolecular interactions. Therefore, T1 agents (Gd3 com-
plexes) are more favorable with respect to the time course of
the Ca-dependent MR imaging response.26 The design of all
Gd3-based Ca2 ionsensitive probes reported so far in-
volved changes in the coordination sphere of the Gd3 ion
following coordination of Ca2. The probes integrate 2 coor-
dinating units that selectively chelate Gd3 and Ca2 ions. In
the absence of the sensed Ca2 ion, 1 (or more) of the donor
groups of the Ca chelating center is weakly coordinated to the
Gd3 ion. On interaction with Ca2, this donor group will
switch from Gd3 to participate in the Ca2 coordination,
thus liberating 1 coordination position on the Gd3 ion. The
coordination position becoming free around the Gd3 is im-
mediately occupied by a water molecule (Fig 4A), and the in-
crease of the hydration number results in a relaxivity increase.
This approach was used in the design of a series of compounds
with 2macrocyclic chelators connected by a spacer containing
a Ca-selective chelating unit. The first example was reported
by Li et al.27 Their sensor responded to Ca2 in the micromo-
lar range, corresponding to intracellular concentrations.
However, not only the intracellular delivery of the agent is
problematic, but given the low relaxivity of the agent, it is not
MR imagingdetectable at micromolar concentrations,
which would be needed to sense Ca2 in the micromolar
range.
Targeting the extracellular Ca2 seemsmore reasonable for
MR imaging applications. The concentration of free extracel-
lular Ca2 is in the millimolar range and drops up to 30%–
35% from the resting state during intense stimulation (typi-
cally from 1.2 to 0.8 mmol/L).9 Sensing Ca2 changes at
millimolar concentrations is more compatible with the rela-
tively high concentrations of the magnetic imaging probe
needed to detect contrast changes. Furthermore, targeting ex-
tracellular Ca2 also simplifies the chemical design, because
additional requirements for cell internalization can be ne-
glected. A series of Gd3 complexes have been reported for
extracellular Ca2 sensing28-31; the best compounds show
10% relaxivity change under biologically relevant condi-
tions (in brain extracellular fluid, for a Ca2-concentration
change between 0.8 and 1.2mmol/L) with a high selectivity for
Ca2, which could already be detectable on MR images.
Zn Sensing
Zn is the second most abundant transition metal in the body,
and its highest concentrations occur in the brain. Neuronal
zinc is partitioned into 2main classes: a static pool of Zn that is
tightly bound to various metalloproteins and a labile pool of
Zn that is mobile. More than 90% of the Zn2 found in the
brain and the body is classified as static, playing structural
roles in transcription factors and related proteins and struc-
tural and catalytic roles in enzymes. The primary source of
labile Zn2 in the brain is from Zn2 release into the synapse
during transmission and can reach concentrations of 200–
300 mol/L. Exposure to uncontrolled concentrations of a
labile pool of Zn2 can lead to excitotoxic neuronal death,
particularly during epileptic seizures, head trauma, cerebral
ischemia and reperfusion, and related situations of overin-
tense neural activity.11 In addition to these, long-term distur-
bances inZn2homeostasis have also been implicated in aging
and age-related neurodegenerative diseases such as Alzheimer
disease. Indeed, the Zn2 ion can reach 1 mmol/L concen-
tration in amyloid plaques and is implicated in their formation
by aggregation of the amyloid- peptide.32
As for Ca2, the main strategy to detect Zn2 ions is based
on a change in the number of water molecules directly bound
to the Gd3 center of a bipartite responsive agent (Fig 4A).
Hanaoka et al studied a system based on the association of a
DTPA core and TPEN as a specific Zn2 chelator. The main
drawback of this system is that it can form 1:1 and 2:1 Zn:Gd-
complex adducts leading respectively to a decrease and a fur-
ther increase in relaxivity on Zn2 complexation. This situa-
tion is problematic because one can reach the same relaxivity
value for 2 different amounts of Zn2.33 The system has been
further modified to replace 1 pyridine unit of each TPEN by a
carboxylate function, to solve this problem.34 Similarly,Major
et al studied a series of macrocyclic complexes associated with
various Zn2 chelators such as TPEN or a diaminoacetate
arm. They showed that at least 1 acetate arm involved in Zn2
Fig 4. Illustration of 2 different strategies to modulate relaxivity of Gd3 complexes by cation recognition. A and B, Change in the q (A) and change in the size, hence the R (B). The binding
site for the sensed metal ion has to be highly selective with respect to other endogenous cations.
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chelation was necessary to observe an increase in relaxivity of
about 100% on Zn2 coordination.35 These probes have not
been tested in vivo, but the in vitroMR images showed that the
diaminoacetate system is sensitive enough to detect physiolog-
ically relevant concentrations of Zn2 (100 mol/L).36 One
highly sensitive PARACEST agent responsive toZn2has been
reported by Trokowski et al.37 The Zn2 chelator consists of 2
TPENunits linked to a cyclen core for Eu3 complexation. On
Zn2 binding, the PARACEST behavior undergoes dramatic
changes.37 It was explained by an acceleration of the proton
exchange, though the underlying mechanism has not been
identified. The system is selective for Zn2 overMg2 or Ca2
ions and is estimated to be able to detect changes in concen-
tration of labile Zn ranging from 5 nmol/L to 0.12 mol/L.37
Fe Sensing
Fe is themost abundant transitionmetal in the body and in the
brain. Indeed, this organ has the highest rate of oxidative me-
tabolism in the body and uses Fe as a key component of en-
zymes involved in oxygen transport andmetabolism. Biologic
iron is most commonly found in the 2 (ferrous) and 3
(ferric) oxidation states. Fe2/3 concentrations in the extra-
cellular environment are in the low micromolar range in the
CSF and are typically between 20 and 30 mol/L in the blood
serum of a healthy adult. Intracellular Fe concentrations in
neurons range from 0.5 to 1 mmol/L. The major part of Fe in
the brain is tightly held by the storage protein ferritin. Ex-
changeable Fe in the brain has been proposed to exist in the
intracellular environment, in a store termed the “labile iron
pool,” containing Fe bound by small anions (PO4
3, CO3
2,
citrate), polypeptides, and surface components of membrane.
However, the existence of this pool is still under active de-
bate.11 Fe undoubtedly accumulates in the brain with age and
is associated with neurodegenerative diseases, including Alz-
heimer and Parkinson diseases.
Because the coordination chemistry of Fe2 and Fe3 is
very different, sensors have to be developed specifically for
each oxidation state. Fe2 is well known for forming stable
complexes with phenanthroline, bpy, and tpy ligands in 1:3
and 1:2 metal:ligand ratios. When attached to Gd3 chelates,
such ligands can promote the formation of supramolecular
assemblies in the presence of Fe2. Despite the fact that these
systems were mainly studied as contrast agents for imaging at
highmagnetic fields, they could potentially be used for sensing
Fe2 ions. Indeed, these assemblies formed around the Fe2
core have a larger size than themonomer Gd3 complex alone
(Fig 4B), which results in a reduced rotationalmobility leading
to a relaxivity enhancement. In the case of the phenanthroline
derivatives, an increase of 90% in the relaxivity is observed on
the formation of the heterobimetallic tris complex.38 The same
phenomenon was observed for bpy and tpy derivatives. The
former shows an increase of about 200% at 40 MHz on the
formation of the heterobimetallic complex (metallostar), giv-
ing rise to an exceptionally high relaxivity confined to a small
molecular space.39,40 This high in vitro relaxivity is retained
under in vivo conditions in mice. The pharmacokinetics of
this metallostar, injected intravenously, were found to be sim-
ilar to that of Gd-DOTA, involving fast renal clearance and a
leakage to the extracellular space in the muscle tissue.41 Re-
cently, another high-molecular-weight tetrametallic su-
pramolecular complex [(Gd-DTPA-phenantroline)3Fe] has
been obtained on self-assembly around 1 Fe2 ion. The slower
elimination of the compound from rats as compared with Gd-
DTPA was found to correlate with a reduced volume of distri-
bution and suggests that the complex is confined to the blood
compartment.42
Another strategy to detect Fe2 ions uses a molecule in-
cluding 3 Gd3-containing moieties linked together by a tris-
hydroxamate unit, which is a strong binding agent for Fe2.
This approach relies on a concept similar to that schematized
in Fig 4B; however, here the Gd3 complexes can be found in
1molecular entity. Thismolecule is very flexible, resulting in a
limited relaxivity. On chelation of Fe by the tris-hydroxamate,
the whole system becomes highly rigid, thereby restricting
flexibility of the entire assembly. This results in about 60% of
the relaxivity increase at 20 MHz, without changing the mo-
lecular weight of the molecule.43
Concerning detection of Fe3, only 1 system has been de-
scribed on the basis of DTPAbis salicylamide. The relaxivity
increases on the formation of the Fe3-bound complex due to
the increase in the molecular weight. The main drawback of
this system is its pH-dependency.44
Cu Sensing
Cu is the thirdmost abundant transitionmetal in the body and
in the brain, with average neural Cu concentrations on the
order of 0.1 mmol/L. Like Fe, Cu can be found in 2 different
oxidation states,1 (cuprous) and2 (cupric); the former is
more common in the reductive intracellular environment,
whereas the latter is dominant in the more oxidative extracel-
lular environment. Cu is partitioned into tightly bound and
labile pools, and free Cu can be released into the synapse on
presynaptic excitation, reaching 15–30 mol/L in the syn-
aptic cleft.11 The normal brain extracellular concentrations are
in the range of 0.2–1.7 mol/L, but like Zn, Cu was found in
high concentrations (400 mol/L) in amyloid plaques that
are involved in Alzheimer disease.32 Disruption of Cu ho-
meostasis is implicated in other neurodegenerative diseases,
including Parkinson disease, familial amyotrophic lateral scle-
rosis, Menkes disease, and Wilson disease.45
NoMR imaging contrast agent has been proposed for Cu
sensing. For Cu2 detection, a single MR imaging contrast
agent has been described in the literature. This Gd3 complex
also functions on the basis of a change in the hydration num-
ber on Cu2 coordination (Fig 4A). The ligand is composed of
a macrocyclic core of complex Gd3 coupled with a pendant
iminodiacetate arm for Cu2 binding. In the presence of
Cu2, this arm de-coordinates fromGd3, leading to a higher
hydration number and a subsequent increase in relaxivity.46 In
a typical experiment, the addition of 30-mol/L Cu2, the
estimated concentration released during neural activity, to a
0.21-mmol/L solution of complex gave a 9% relaxivity in-
crease, a value which might be suitable for in vivo imaging
applications. However, so far, to our knowledge, no in vivo
MR imaging experiments have been reported for Cu sensing.
pH-Sensitive Probes
The potential use of pH-sensitive probes is vast, though so far
pH mapping of tissues has been mainly intended to facilitate
cancer detection and assess the tumor status. Indeed, the pH
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on the surface of tumors is0.4 units lower than that in nor-
mal tissue, but in some cases, it can be as low as 6.0.47 On the
other hand, pH-sensitive probes could also indicate neuronal
activity because they induce a slight acidification of the extra-
cellular medium (pH 7.2–7.4).48 One could also imagine the
use of pH-responsive probes to determine if the brain envi-
ronment is suitable for a drug that functions in a pH-sensitive
environment.
The design of pH-sensing probes has been an intensive
field in MR imaging contrast agent research. Nonexhaustive
examples are provided.49-55 Some of the pH probes also
proved useful for in vivo application. The combination of
the pH-sensitive amido-phosphonate derivative of Gd-DOTA
and a pH-insensitive analog was used in a dual injection to
image renal pH in mice.56,57 The assumption was made that
both compounds have comparable pharmacokinetics; hence,
the concentration of the former can be inferred from the con-
centration of the latter. This mixture has been also used to
obtain extracellular pH MR imaging maps in a rat glioma
model, with improved spatial resolution compared with spec-
troscopic methods.58 Differences of the order of 1 pH unit
could be detected; the absolute pH values have been calculated
by using a calibration method.
A key factor determining the effectiveness of an agent is the
difference between the relaxivity of the “on” state compared
with that of the “off” state. Recently, the amplitude of the
relaxivity response to pH variation of this low-molecular-
weight probe has been largely improved (more than doubled)
by conjugating it to amacromolecular dendrimeric scaffold.59
However, improving the relaxivity response to pH through
increased molecular weight may also negatively impact the
effectiveness of such agents. Large molecules, such as den-
drimers, remain in the vasculature longer than discrete agents,
which are better able to diffuse into all extracellular space.
Furthermore, large molecules also tend to clear more slowly
from the body as a result of increased liver uptake. This ex-
tends the retention time of Gd3 in the body. Further studies
into the in vivo behavior of dendrimer-based MR imaging
contrast media will be required to establish whether this ap-
proach, which is successful for increasing the relaxivity re-
sponse, will yield agents that can actually be applied in vivo.
PARACEST agents have a great potential to indicate pH.
The PARACEST effect originates from proton exchange be-
tween the paramagnetic probe and water, and the magnitude
of the observed effect is intrinsically dependent on the ex-
change rate, itself related to pH.60 Unlike traditional Gd3-
based agents, it is possible to administer and independently
visualize 2 PARACEST agents in the same experiment and
thus develop a concentration-independent ratiometric
method for pH determination. For instance, one can acquire
the PARACEST pH profiles for a cocktail of 2 isostructural
probes, including an identical ligand but 2 different paramag-
netic metal ions. The individual PARACEST response of the 2
probes to pH will be different, whereas their distribution in
tissue should be identical. Consequently, the ratio of the 2
PARACEST profiles is concentration-independent and can be
used to determine pH directly without knowing the analytic
concentration of either agent. In some cases, the 2 proton
pools giving rise to the 2 PARACEST effects can be found
within a single molecule, which further simplifies the pH
measurement.4,61,62
Enzyme-Activated Contrast Agents
Among all responsive agents, enzyme targeting represents a
specific advantage, which is particularly valid for MR imaging
detection, given its low sensitivity. A small concentration of
the enzyme can catalytically convert a relatively high amount
of the enzyme-responsive magnetic probe, which markedly
decreases the limit of detection for the enzyme compared with
other biomolecules. In addition, the high specificity of enzy-
matic reactions means that the observed change in the MR
imaging properties can be unambiguously attributed to the
targeted enzyme. The presence of certain enzymatic reactions
indicates the cellular state and can provide the signature of a
given pathology. Therefore, the real-time noninvasive in vivo
detection of specific enzymatic activities would have invalu-
able diagnostic impact. As an example, the importance of en-
zymatic activity has been established in the processes of tumor
formation, growth, and metastasis. Molecular biology studies
have defined enzymatic steps of the apoptotic response to an-
ticancer therapies in vitro and in vivo. The detection of gene
markers (such as- galactosidase) could be another important
field of application.
The first enzymatically responsive potential MR imaging
contrast agent was a Gd-DOTAderivative bearing a galacto-
pyranose residue that prevents water coordination.63,64 This
sugar moiety is a substrate for the enzyme -galactosidase. Its
enzymatic cleavage by -galactosidase opens the access of wa-
ter to the first coordination sphere of Gd3, resulting in a
relaxivity increase, thus irreversibly activating the agent. It has
been successfully used for the in vivo detection of -galacto-
sidasemessenger ribonucleic acid expression in livingXenopus
laevis embryos.
Among other examples, Anelli et al65 functionalized Gd-
(DTPA)2with sulfonamide, which is known as a specific car-
bonic anhydrase inhibitor. The agent reacts with carbonic an-
Fig 5. An example of an enzyme-activated PARACEST contrast agent: The enzyme specifically reacts with the substrate leading to the spontaneous elimination of the self-immolative linker.
This gives rise to a change in the PARACEST properties.
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hydrase, and thus targets enzyme-rich tissues. Nivorozhkin et
al66 reported the enzymatic transformation of a prodrugGd3
complex with poor affinity to HSA and low relaxivity to a
species with improved HSA affinity and enhanced relaxivity.
In this approach, the origin of the relaxivity increase was the
slower rotation for protein-bound chelates with respect to
the small-molecular-weight prodrug. The same concept was
applied for the detection of alkaline phosphatase.67 Mazooz et
al68 described a Gd-DTPA peptide acting as a transglutami-
nase substrate, which was used to monitor transglutaminase
activity. Shiftan et al reported MR imaging visualization of
hyaluronidase in ovarian carcinoma,69 related to the aggres-
siveness of ovarian cancer metastasis. Chen et al70 visualized
plaque rupture in atherosclerosis with a Gd-DOTA
serotonin derivative, which polymerizes in the presence of
neutrophil myeloperoxidase, resulting in a remarkable relax-
ivity increase. Tyramido or tryptamido derivatives of Gd-
DTPA were proposed as enzyme-activated agents for peroxi-
dase imaging.71
Another concept for enzyme detection is based on the self-
immolative mechanism. Duimstra et al72 reported a Gd3
complex with a self-immolative moiety, designed for the de-
tection of -glucuronidase. PARACEST agents with a re-
sponse to enzymatic activity have also been reported. Yoo and
Pagel73 and Yoo et al74 used a thulium-DOTA-monoamide
complex containing a peptide chain, which is hydrolyzed by
the caspase-3 enzyme. Following enzymatic cleavage, the
PARACEST effect originating from the amide proton disap-
pears due to the hydrolysis of the amide bond.
In another example, the lanthanide complex has been
linked to an enzyme-specific substrate via a self-immolative
spacer (Fig 5).75 With benzyloxycarbamates as a self-immola-
tive unit, the substrate can be any enzyme-recognized moiety
capable of transitionally reducing the electron donor capabil-
ities of the phenyl substituent. The enzymatic cleavage of the
substrate initiates an electron cascade and leads to the sponta-
neous elimination of the spacer. This results in the appearance
of a PARACEST effect attributed to the exchange of the amine
protons. This platform represents several positive features: the
substrate is at the extremity of a spacer, which facilitates
the enzymatic cleavage, and the PARACEST properties will
not be affected by the variation of the substrate. Because the
PARACEST effect is observed after enzymatic activation, it can
be optimized once for the whole family. The same lanthanide
chelate and spacer can be applied for the detection of diverse
enzymes, by varying the substrate. The system works as a
switch off-on probe, which can be a further advantage in prac-
tical in vivo or in vitro applications.
Redox Responsive Agents
It is widely believed that hypoxia is an important factor gov-
erning tumor aggressiveness and that hypoxic tissue is more
resistant to conventional therapeutics.76-78Methods for imag-
ing tumor redox status would allow the noninvasive applica-
tion of this potential biomarker of tumor sensitivity to existing
and novel chemotherapies, as well as radiation therapy. The
utility of suchmethods could also extend to other pathologies,
such as cardiovascular disease, because free radical formation
is associatedwith deleterious effects on the coronarymicrocir-
culation during recovery from myocardial infarction.79
Hypoxia is mostly detected by imaging techniques includ-
ing positron-emission tomography and BOLD MR imaging.
Reports on redox-sensitive MR imaging contrast agents have
been rather scarce. The simplest design of a redox-responsive
MR imaging contrast agent could be based on metal com-
plexes whose metal ion can be reduced or oxidized depending
on the biologic environment in which the 2 oxidation forms
have different relaxation properties. Thus, the 2 redox states
influence the proton relaxation of the surrounding protons to
a different extent, resulting in different image intensities. In
this perspective, the adducts formed between tpps complexes
of Mn (III) and Mn (II) and poly--cyclodextrin have been
reported to have considerably different relaxivities depending
on the redox state of the metal, itself determined by the partial
oxygen pressure of the solution.80 More recently, DOTA-
based complexes of Gd bearing a thiol moiety were synthe-
sized, and it was hypothesized that these complexes would
form reversible covalent linkages with HSA, which contains a
reactive thiol at cysteine-34. This redox-sensitive reversible
binding of Gd complexes to plasma albumin could be ex-
ploited for imaging the tissue-redox state.81
Recently, the first example of a redox-active responsive
PARACEST agent has been reported by Ratnakar et al.82 The
system is based on a DOTA-derivative Eu complex bearing a
nitro group, which can be reduced under hypoxic conditions
to an amine. The authors demonstrated that there is a clear
difference in the PARACEST signal intensity between the ox-
idized nitro and the reduced amino derivative. They suggest
that the PARACEST difference generated by the chemically
reducible probe could be exploited to design biologically ap-
plicable redox-responsive imaging agents.
Conclusions
A large number of activatable smart Gd3-based or PARACEST
MR imaging probes with potential utility for molecular neu-
roimaging applications have been reported in the literature. So
far only a very few of them have progressed to in vivo tests.
Future work will likely focus on extending applications of
these agents to living animals, as well as on exploring newways
of creating molecular MR imaging probes to meet require-
ments such as higher specificity or lower detection limits. Ul-
timately these advances may allow spotting disease-causing
abnormalities before any symptoms surface. Molecular imag-
ing agents could speed up the advent of personalized medi-
cine, in which therapies are tailored to individual patients and
doctors can monitor the impact of treatment on a molecular
scale.
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